Clinical trials: Myelodysplastic Syndrome(MDS), open to volunteers
Myelodysplastic Syndrome (MDS)
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
[Tolerability Assessment Part] The purpose is to identify the doses of the oral azacitidine(AZA) formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2.
- Trial name
- NCT04608110
- Testing
- ASTX030 (AZA + CED)
- Where
- 10 sites in Japan
- Volunteers
- 59 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.
- Conditions
- B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma
- Trial name
- NCT05092451
- Testing
- Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS)
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic…
- Trial name
- NCT07753148
- Testing
- REGN17235
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML
This study aims to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome, subcutaneous cytarabine and G-CSF combined with venetoclax (CMG+Ven) versus azacitidine combined with venetoclax (VA) in the treatment of…
- Trial name
- NCT07735117
- Testing
- Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF)
- Volunteers
- 168 people
- Sponsor
- Ruijin Hospital
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia)
PRAISE-IR Versus CIBMTR Controls
The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07717164
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Miltenyi Biomedicine GmbH
Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
Caris Chromoseq Data Collection
The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplatic Syndromes, Myeloproliferative Neoplasm
- Trial name
- NCT07680868
- Testing
- Caris Chromoseq
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Caris Science, Inc.
Myelodysplastic Syndromes (MDS), Beta-thalassemia
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: Participants receiving luspatercept on a parent protocol at the time of their transition to the…
- Conditions
- Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
- Trial name
- NCT04064060
- Testing
- Luspatercept
- Where
- 143 sites in United States, Australia and 20 more
- Volunteers
- 665 people
- Sponsor
- Celgene
Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and…
- Conditions
- Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET), Acute Myeloid Leukemia
- Trial name
- MYELO-CAN:ABX (NCT07528417)
- Testing
- Levofloxacin, Usual Care
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University of Manitoba
MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Haplo-Cord HSCT for AML/MDS
This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze…
- Trial name
- NCT07588360
- Testing
- haplo-cord HSCT, Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
- Where
- 4 sites in China
- Volunteers
- 82 people
- Sponsor
- Fujian Medical University Union Hospital
Acute Myeloid Leucemia, High-risk Myelodysplastic Syndrome (MDS)
Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital
The aim of the LANA bio-collection is to collect samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) or or high-risk myelodysplastic syndrome (MDS) to facilitate access to the leukemic or…
- Conditions
- Acute Myeloid Leucemia, High-risk Myelodysplastic Syndrome (MDS), Acute Lymphoid Leukemia
- Trial name
- LANA (NCT06681363)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Nantes University Hospital
AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
This study will explore the efficacy and safety of ivosidenib as maintenance therapy in patients with IDH1-mutated AML and high-risk MDS who are ineligible for transplantation, along with accompanying molecular biomarker…
- Trial name
- NCT07607418
- Testing
- Ivosidenib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made.
- Trial name
- NCT04187703
- Testing
- 5-azacytidine, Decitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Benjamin Tomlinson
AML, MDS
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide…
- Conditions
- AML, MDS, Acute Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07493538
- Testing
- Treosulfan, Fludarabine, Total Body Irradiation
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
This is an open-label, single-center, non-randomized phase I/II pilot study evaluating proton-based Total Marrow Irradiation (TMI) as part of the conditioning regimen prior to allogeneic hematopoietic stem cell transplantation…
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Proton Therapy, MDS and AML Prior to Allogeneic SCT
- Trial name
- UHKT-PTC-TMI-1 (NCT07532824)
- Testing
- Proton Total Marrow Irradiation
- Where
- 2 sites in Czechia
- Volunteers
- 16 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Leukemia, High Risk Acute Lymphoblastic Leukemia
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections.
- Conditions
- Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia
- Trial name
- NCT06839456
- Testing
- Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's Hospital of Philadelphia
MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA)
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
This study is for adults aged 18-65 with myelodysplastic syndrome (MDS) or severe aplastic anemia (AA) who are scheduled to receive a donor stem cell transplant (allogeneic hematopoietic stem cell transplant).
- Trial name
- PROMPT (NCT07400341)
- Testing
- Romiplostim, Recombinant Human Thrombopoietin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
Acute myeloid leukemia (AML) is one of the most common hematologic malignancies. With increasing life expectancy and the aging of society, the incidence of AML in the elderly population is rising.
- Trial name
- NCT07500753
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Myelodysplastic Syndrome (MDS)
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS)…
- Trial name
- NCT02944955
- Testing
- BLEX 404 Oral Liquid
- Volunteers
- 52 people
- Sponsor
- BioLite, Inc.
Myelodysplastic Syndromes (MDS), Anemia
Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes
This study is a prospective, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of dapagliflozin in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS).
- Trial name
- DAPA-MDS1 (NCT07516847)
- Testing
- Dapagliflozin (10mg Tab)
- Volunteers
- 37 people
- Sponsor
- Seug yun Yoon, MD
MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment
Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia.
- Trial name
- WATCH Tranfuse (NCT07511829)
- Testing
- Axvitiy Ax3 accelorometer
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Oxford